United Therapeutics (UTHR) CEO Rothblatt Buys $1.4M of Stock

CEO Martine Rothblatt Expands Stake With June Purchase

United Therapeutics Corporation Chief Executive Officer Martine Rothblatt acquired 9,500 shares of the biotechnology company on June 16, 2026. The transaction carried a price of $146.03 per share, totaling approximately $1.39 million. This buy fits into a wider pattern of active personal share management by the company's chief executive throughout the middle of the year.

A Closer Look at Recent Insider Activity

The June purchase fits into a busy sequence of trades by the executive across 2026. On June 22, 2026, Rothblatt picked up another 9,500 shares valued at $1.32 million, followed by identical 9,500-share acquisitions on June 25, 2026, and June 26, 2026, worth $1.29 million each. Alongside those buys, the CEO also recorded planned and unplanned dispositions of 9,500 shares on dates such as June 22, June 26, and a later planned sale of 9,500 shares on October 14, 2026, valued at about $5.13 million.

Stock Performance and Valuation Context

Shares of United Therapeutics trade on the NasdaqGS under the ticker UTHR with a spot price of $551.47. The stock sits well within its 52-week range, which stretches from a low of $409.07 up to a high of $609.35. The company carries a price-to-earnings ratio of 17.67 and a forward P/E ratio of 16.42, alongside a modest beta of 0.56 that points to lower price swings than the wider market.

Recent Earnings and Financial Health

United Therapeutics posted total revenue of $3.15 billion over the reporting period, accompanied by a revenue dip of 1.9%. The enterprise maintains strong profitability with a net margin of 41.56% and a return on equity of 19.32%, supported by earnings of $27.90 per share. Investors look ahead to the next financial results release scheduled for October 28, 2026.

Analysts Set New Price Targets

Wall Street firms frequently update their outlooks for UTHR as leadership trades shares. On October 8, 2026, RBC Capital maintained an Outperform rating while raising its price target to $708.00 from $677.00. Days earlier on October 7, 2026, Morgan Stanley kept an Equal-Weight rating and lifted its target to $566.00. BTIG initiated an upgrade to a Buy rating with a $728.00 target on October 1, 2026, while Goldman Sachs started coverage with a Sell rating and a $321.00 target on September 24, 2026. Across twelve analyst opinions, the stock holds a consensus recommendation of buy with a mean price target of $664.33.

Inside the Business

Headquartered in Silver Spring, Maryland, United Therapeutics develops specialized treatments for severe and chronic medical conditions. Its portfolio features therapies for pulmonary arterial hypertension such as Tyvaso, Remodulin, and Orenitram, alongside oncology products like Unituxin. The company also invests in advanced organ technology, including gene-edited xenotransplantation research.

What to Watch at United Therapeutics Corporation

Market participants will monitor upcoming disclosures from the company's leadership team and track the upcoming quarterly financial update on October 28, 2026. Insider transactions provide visibility into how executives manage personal equity, though they reflect past decisions rather than guarantees of future stock behavior.